Newsfilter·2025-03-06 21:22Core Viewpoint - Fennec Pharmaceuticals Inc. is set to release its full year and fourth quarter 2024 financial results on March 10, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing PEDMARK®, which aims to reduce the risk of platinum-induced ototoxicity in pediatric patients [3]. - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3]. - The product has been granted Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [3]. Conference Call & Webcast Details - The conference call is scheduled for March 10, 2025, at 8:30 a.m. Eastern Time, with a live webcast available [2]. - Participants are advised to connect to the company's website at least 15 minutes prior to the call for any necessary software downloads [2]. - A replay of the conference call will be archived on the company's website for thirty days [2].